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Background: Little is known about the experience of young women who become aware of their parent’s BRCA1
or BRCA2 (BRCA) mutation status as adolescents or young adults. There is also currently a gap in the literature
pertaining to those who are found to be negative for their familial mutation. We aimed to investigate the
experience of these mutation-negative young women from hereditary breast and ovarian cancer (HBOC) families.
Methods: Using a semi-structured questionnaire we interviewed 8 women. All of the women were non-carriers of
their familial mutation and had learned of the mutation in their family as adolescents or young adults at least 6
months prior to undergoing genetic testing. All interviews were audio recorded, transcribed, and independently
analyzed by the investigators. This was followed by an in-depth cross-case analysis, enabling the formulation of
emergent themes.
Results: The women’s age ranged from 22 to 37 years old and all were of Ashkenazi Jewish descent. Prominent
emergent themes from the interviews included the impact of how and when the familial mutation status was
disclosed, the factors influencing when a young woman chooses to undergo predictive genetic testing, the
predictors of post-test adjustment and risk perception, as well as the impact of familial cancer experience versus the
familial mutation.
Conclusions: By eliciting detailed patient narratives we have begun to show that this generation of BRCA
mutation-negative young women is likely still affected by the degree of cancer history in their family, even with
their understanding of the genetic contribution to disease. Larger studies with tightened participant characteristics,
as well as studies involving women from different cultural backgrounds, are needed to further define the
experience and needs of true negative young women from HBOC families.
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Since the discovery of the BRCA genes in the mid 1990’s
much information has been gained regarding the cancer
risks to both men and women who carry a germline muta-
tion in one of these two genes. The greatest risk is for
women where mutation carriers have about a 50-85% risk
before the age of 70 years of developing breast cancer and
about a 10-45% risk of developing ovarian cancer [1].* Correspondence: lmacrae@jgh.mcgill.ca
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reproduction in any medium, provided the orMutations in the BRCA genes are inherited in an auto-
somal dominant manner and, as a consequence, each child
of a germline mutation carrier has a 50% risk of inheriting
the mutation from their parent. Thus, one of the greatest
concerns for individuals after learning that they carry a
BRCA mutation is the risk that their children might inherit
the mutation.
It is known that parents often disclose their carrier status
to their adolescent children, especially mothers to their
daughters [2-5]. However, there have been few studies
looking at the effect that this disclosure has on children
and adolescents as they mature. What has been found is
that some adolescents who learn of their parent’s mutationLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Macrae et al. Hereditary Cancer in Clinical Practice 2013, 11:14 Page 2 of 11
http://www.hccpjournal.com/content/11/1/14status respond adaptively and might improve their health-
related behaviour as they transition into adulthood [6].
However, little is known regarding what becomes of these
adolescents as they grow to be young adults carrying the
knowledge that their parent carries a BRCA mutation. Of
particular interest here are the views of women growing up
with the possibility of being at high risk for developing can-
cer and how this experience might influence the various as-
pects of their lives.
Given that approximately half of all women with a par-
ent who carries a BRCA germline mutation will be nega-
tive for the gene mutation, an equally important area of
research is the understanding of risk perception among
non-carrier women from HBOC families. Studies have
found that middle-aged women who have grown up with
a strong family history of breast and/or ovarian cancer
often have difficulty identifying with a population risk of
cancer when they are found to be negative for their fa-
milial BRCA mutation [7]. This difficulty in accepting a
lower risk is thought to be the result of a long period of
cancer awareness in the family. In addition, these older
women have only just come to understand the more re-
cent possibility of the contribution of a BRCA mutation
to their breast and ovarian cancer risk and might have
greater difficulty incorporating this knowledge into their
perception of cancer risk. It is well known that a close
familial experience of breast cancer has a strong influ-
ence on a woman’s identity and how they perceive their
own cancer risk [8,9]. In some cases, a genetic test might
do little to erase the decades of disease experience
present in the family or alter one’s cancer screening
practices.
Similarly, prior to the discovery of the BRCA genes,
adolescent girls developed a sense of cancer risk based
on their family history and personal proximity to the
disease. However, the era has now shifted where young
girls might not only experience a family history of the
disease, but are also growing up with the understanding
of the underlying genetic cause. These young women
can, in turn, decide to be tested for the underlying gen-
etic contribution to cancer in their family. For the
women who choose to be tested, those who learn they
are mutation-negative might adapt differently to their
test result than the middle-aged women previously de-
scribed. However, given that many variables are known
to be associated with risk perception [10], it is unclear if
the knowledge and the understanding of genetic risk will
affect identity and risk perception in the same way that
family history alone has affected previous generations.
In 2003, an integrative review of the psychosocial as-
pects surrounding genetic testing for BRCA mutations
concluded that there was a need to more systematically
collect data on all those seeking genetic testing, includ-
ing those who are found to be mutation-negative [11]. Adecade later little has been gained with regard to under-
standing the experience of women who are BRCA
mutation-negative. The main objective of the article is to
understand the impact of being a non-carrier in young
women from HBOC families. We report here on how
this has shaped their lives, their risk perception prior to
and post genetic testing, as well as the general effects of
being a non-carrier from an HBOC family.
Methods
Research design
The study design was that of an exploratory cross-sectional
qualitative analysis of individual interviews conducted with
8 participants ascertained through the Cancer Prevention
Centre at the Jewish General Hospital in Montreal, Canada.
Eligible women were those with a negative mutation status
from a HBOC family, having learned of the mutation in
their family before the age of 25 and at least 6 months prior
undergoing predictive genetic testing. Data for each case
were obtained using a modified semistructured McGill Ill-
ness Narrative Interview (MINI) [12]. The MINI model for
conducting semistructured interviews is designed to elicit
broad, yet detailed, patient narratives that allow researchers
to examine the meaning participants give to their illness ex-
perience, as well as the impact that their experience has
had on them [12]. Data obtained from each interview were
analysed and coded individually followed by an in-depth
cross-case analysis enabling the formulation of emergent
themes. Approval for the study was obtained by the hos-
pital institutional review board.
Patient population
The participants were women recruited from the Depart-
ment of Medical Genetics at the Jewish General Hospital.
An attempt was made to identify women who were chil-
dren or adolescents when their parent underwent genetic
testing. We examined the pedigrees of mutation carriers
who were between the ages of 25 and 40 at the time of gen-
etic testing at least 5 years prior to recruitment for the
study in 2010. This age category was chosen to increase the
likelihood that their potential children would have been
young at the time they were tested. We then verified if any
had daughters who were tested at our institution and found
not to carry their familial mutation. Eight potential partici-
pants were identified. The 8 women were contacted by
phone by the principal investigator, at which time all ver-
bally consented to an interview with the co-investigator. All
8 women subsequently participated in the interview process
and their signed consent was obtained at the time of the
interview. The interviews were conducted by a single inves-
tigator either at the Jewish General Hospital or at a location
chosen by the patient. One interview was conducted via
Skype. All participants were English-speaking, of Ashkenazi
Jewish descent, and had at least one first degree relative
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from 22 to 37 years old (mean age 28.5 years). All had some
form of postsecondary education. Four were married at the
time of the interview, of whom three had two children each
(Table 1).
Data collection
Semistructured interviews were conducted using a modi-
fied version of the MINI, where “illness” was replaced
with “genetic status” or “family history of cancer.” When
appropriate, probing and exploration of relevant experi-
ences shared by the participants was performed by the
interviewer. As the interviews and data collection
progressed, new probes and questions were formulated
to elicit experiences surrounding emerging themes from
previous interviews. The length of the interviews ranged












Family history of breast/ovarian cancer
Yes 8





Communication of familial mutation
By at least one parent 6
Self-discovered 2
Knowledge of mutation status in the family prior to testing
Less than 1 year 2
Between 1–4 years 1
Between 5–10 years 3




Other 0minutes. The recorded interviews were subsequently
transcribed verbatim for thematic content analysis and
interpretation.
Data analysis
Each transcript was transferred to a computer software
program, Atlas.ti 5.2 used for coding and analysis. The
complete transcript of each interview was read and
coded independently by the principal investigator and
the coinvestigator. Validation of the independent coding
process through the random sampling of 30 passages
from 2 interviews produced an agreement of 81% be-
tween the two investigators. The categories and themes
produced by the coding process were derived induct-
ively. During the coding process, codes were merged to-
gether, updated, and evolved as the data analysis
progressed. After the coding was completed, thematic
networks involving all transcripts were created, which
allowed for the visualization and interpretation of emer-
gent themes.
Results
Several themes emerged from the raw data following
coding and thematic analysis. A comprehensive list of
emergent themes is available in Table 2.
How and when parents should disclose their mutation status
All participants believed that the genetic information in the
family is something they should learn about and most
expressed a desire for this information to be disclosed to
them by both parents. Overall, participants recalled that
limited information was provided at the initial time of dis-
closure and only gradually did they obtain more informa-
tion from their parent or from an outside source.
Participants spoke about the benefits of knowing about the
mutation in the family at a young age, including having
time to process the information and to gain more know-
ledge and understanding over time. Another benefit was
the advantage of having time before the age at which deci-
sions about screening or surgery would have to be made.
Two participants in our sample were not informed by
a parent about their familial mutation. Both of these par-
ticipants expressed the desire to have had both parents
introduce the genetic mutation information directly to
them. The experience of these individuals was that of an
emotionally charged event, which is counter to what was
described by the other 6 participants. They both sought
genetic counseling almost immediately after discovering
the information.
I was like raging mad when I found out. I mean it's
hard, like I'm over it now, so it's hard to be accurate
about like how I felt, but I definitely felt lied to at the
time. (This 22-year-old young woman learned of the
Table 2 List of emergent themes
Theme Example
Timing There is no perfect time to undergo predictive genetic testing
Young women appreciate learning their familial mutation status in adolescence even though concepts might not be
fully understood at that time
A balanced presentation of the genetic information for adolescent or young children is important and information
needs change with time
Having time in between learning a parent’s carrier status and undergoing personal genetic testing is appreciated, as it
is used to process and contemplate the information
Many choose to undergo predictive genetic testing at a time when they can immediately take action if found to be
positive, because cancer is the problem and not the gene itself
Age is an important determinant of when to undergo predictive genetic testing, but opinions about the best age
differ
Disclosure Young women want to learn from a parent, and prefer both parents to be present for the status disclosure of a familial
BRCA mutation
Those not informed by a parent had the desire to be tested soon after discovering their familial BRCA mutation to
gain information that they had been deprived of
Nonparental disclosure and self-discovery of a familial BRCA mutation might generate additional stress
Risk Perceptions Many of the young women believe they are mutation carriers before undergoing testing
Prototypical or familial cancer experience influences pretest and posttest cancer worry and cancer screening desires
All understand their posttest risk of developing breast or ovarian cancer
Cancer Worry Posttest breast cancer worry is reduced with respect to their offspring’s risk, but remains somewhat elevated for
themselves
Posttest cancer preoccupation and worry can be related to pretest levels preoccupation and worry
Most seek an active and healthy lifestyle as a way to influence and control their cancer risk
Cancer Burden Need for supportive counseling because of the lack of social prototype for non-carrier women
The potential of transmitting a genetic mutation to children has an influence on decision to undergo genetic testing
and potential feelings of guilt
Weighing the pros and cons of predictive genetic testing before having children versus after having children
Importance of the impact that genetic testing and genetic knowledge has beyond the individual
Present and future familial and social relationships are an important factor surrounding the decision to undergo predictive
genetic testing
Feelings of survivor guilt are present in these mutation-negative young women
The experience of hereditary breast and ovarian cancer is not over because other family members are carriers or have yet
to be tested
Hope Appreciation for the various generational differences in hereditary breast and ovarian cancer families because of the
gain in knowledge and options with each successive generation
Genetic knowledge is seen as empowering at any age
Ability to bring awareness regarding genetic testing to their families and to others
Plans for the Future Impact of a negative test result on the ability to plan for a future without cancer
Preparation for a positive result with the development of a plan of action and the exploration of potential emotional
reactions to this outcome
Explanatory Models for
Mutation Status
Myths about non-carrier status include paternal contribution and spiritual or theological influence
Most employ a biomedicine-based explanatory model for their carrier status
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documents related to the presence of the mutation in
her mother. She subsequently underwent predictive
genetic testing less than one year later).
[It’s] either [you] have [the] time to deal with it. Like,
process it yourself. And then just, like, take it in, thenbe told what it is. Or it's like: you read it, and you
freak out, not know what it is, and then, it's, you're up
here, and then you're like, ‘Ah, okay. Oooh.’ I don't
know, maybe somewhere in the middle maybe if
you're having a family discussion then they bring it
up. (This 26-year-old participant learned of the
mutation in her family at 20 years old by discovering
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her father. She subsequently underwent predictive
genetic testing less than one year later).
I really appreciate the way my family handled it, being
open about it even if I didn't necessarily grasp it at
the age I was told. I think it's better to know and to
kind of have those years to kind of ease yourself into
the idea…than to be told when there's already, like,
some kind of you know, sickness in the family, or
newly diagnosed individual, because then it's just too
much shock. (This 30-year-old woman learned that
her mother is a mutation carrier in her mid-teens
through an open family discussion. She underwent
predictive genetic more than 10 years later).
Even when my mother did explain it to me, and, I
guess, at the time, she sort of pitched it like, maybe to
soften the blow, in a sense, but just that, if it did
affect us, it was so many years away. Like, we were
only in our twenties. (This 36-year-old woman
learned of the mutation in her family in her mid-
twenties through a discussion with her mother, who
carries the familial mutation. She underwent
predictive genetic testing more than 5 years later).Age is an important determinant for undergoing
predictive genetic testing
Age was most often discussed with respect to the
women’s decision regarding undergoing predictive gen-
etic testing. An important age-dependent determinant
for the timing of testing was the age at which the indi-
vidual perceived being diagnosed with cancer to be an
actual threat, that which was based on their familial or
societal stereotypes of cancer. Other age-dependent fac-
tors were dating, marriage, and both career and family
planning. Undergoing testing at an age that allows one
time before screening and the consideration of surgical
interventions was also important to those advocating
testing at a younger age.
The participants were split on the issue of undergoing
predictive genetic testing prior to versus after having
children. The three women with children at the time of
their interview all agreed that testing should wait until
the completion of one’s family. Proponents of postpon-
ing testing argued that because ovaries and breasts are
needed to have and to nurse children, undergoing
prophylactic surgery prior to having children would not
be an option, therefore genetic testing was not
necessary until after. Those advocating testing before
childbearing argued that the results of such testing
might dictate when and even if having children would
be considered.I wouldn't wanna do [genetic testing] too late.
Because what if you wanna start a family? I would say
you have to do it before you start a family. Because
that could play in your idea of having a family. (This
24-year-old participant learned of the mutation in her
family in her late-teens and underwent predictive
genetic testing at the age of 21. She did not have
children at the time of testing).
Cancer is something that, you know, can affect
anybody. And if you can control a little bit of it by
getting tested younger, I think that people should do
that. Just so that they have more options as they get
older of how to minimize their risks, or to control
some parts of it. (This 22-year-old woman learned of
the mutation in her family in her early-teens and
underwent predictive genetic testing at the age of 21.
She did not have children at the time of testing).
[In] my early thirties, it wasn't as much about critical
timing as if I would have been already in my forties or
later forties. I finished having my kids, and after my little
one was already in daycare. Because, I knew that if I did
the testing, I would have made the decision to have a
mastectomy pretty quickly. (This 37-year-old participant
learned of the mutation in her family in her mid-twenties
and underwent predictive genetic testing at the age of 34.
She had two children at the time of testing).
Posttest adjustment and risk perception
Many of the women believed they were a mutation car-
rier before undergoing predictive genetic testing and felt
a great sense of relief after learning that they were not a
carrier. However, because of the dichotomy created be-
tween their mutation-negative status and their positive
familial status, conflicting emotions of relief, happiness,
guilt, fear, and anger were also present. One participant
even expressed a desire to have been mutation-positive.
They all understood their posttest population risk of
developing breast and ovarian cancer, but some desired
to have additional screening as a result of their familial
cancer experience and residual cancer worry. Despite
this, none were actively seeking further treatment or
screening beyond what is recommended to the general
population for their age category. One participant
expressed a more intense ongoing residual cancer pre-
occupation and worry.
I have trouble believing that I'm going to escape this
lifetime without getting breast cancer. And I should be
thrilled that I'm negative and I am, and as every year
goes on that I don't get breast cancer I know treatments
are getting better and research is getting better and there
is more help out there, but somehow it doesn't make me
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underwent predictive genetic testing in her early thirties
after knowing about the presence of the familial
mutation for more than 10 years. Her mother was
diagnosed with breast cancer at ages 39 and 46).
I don't feel like I need to be hyper-vigilant, or anxious
about [cancer]. I don't know, I think that. I know that
anxiety is not necessarily something that you can
consciously control, but I did get a sense of relief from
being negative and the fact I can, you know, not worry
about this on a daily basis anymore. (This 30-year-old
woman underwent predictive genetic testing at age 27
after knowing about the presence of the familial
mutation for more than 10 years. Her sister was
diagnosed with breast cancer at 29).
But I still have some chance. But at least, you know,
I'm more cautious. Just cause I don't have [the
mutation] doesn't mean anything. A lot of people say,
‘Oh, I don't have [the mutation]. Okay, I'm okay.’
Which is not true. You know, it's just, now your
chances are lower.” (This 26-year-old young woman
underwent predictive genetic testing in her early-
twenties, less than one year after learning about the
presence of the familial mutation. Her father was
diagnosed with breast cancer).
It's one of those things that you've been stressing
about for so long and then afterwards it's one of those
things; it's like a break-up, like you just slowly forget
about it overtime. (This 22-year-old participant
underwent predictive genetic testing at age 20, less
than one year after learning about the presence of the
familial mutation. Her mother was diagnosed with
breast cancer at age 39 followed by ovarian cancer
several years later).How the genetic knowledge has shaped their life
The general feeling among most of the women was that,
even though they are non-carriers, their experience of
the burden of hereditary breast and ovarian cancer is
not over. They explained that their lives continued to be
burdened by new cancer diagnoses in the family and the
identification of other mutation-positive family mem-
bers. Although this is true, many pointed to the fact that
with each subsequent generation there is a gain in know-
ledge. This knowledge of the presence of the gene muta-
tion in the family also shaped their lives in terms of
relationships, dating, marriage, family planning, and hav-
ing to contemplate one’s own mortality at a young age.
Growing up with the knowledge of a genetic mutation in
the family has also motivated at least several of thewomen to become advocates for genetic testing and for
other families burdened by cancer.
I'm lucky enough not to have [the mutation], but it's a
part of my family. It's still a big deal of who we are.
(This 24-year-old participant underwent predictive
testing at age 21 after learning of the mutation in her
family in her late-teens. Her younger sister has yet to
pursue predictive genetic testing).
I always thought that you know maybe if, God forbid,
I have the gene I can get married a little younger, have
kids, you know that way I don't need to be pressured
or rushed to have kids like towards my thirties.
Because if, God forbid, cancer comes around, you
know, I didn't want it to be like a lingering factor
always, though, like in my mind. (This 22-year-old
young woman underwent predictive genetic testing at
the age of 21 after learning about the mutation in her
family in her early-teens. She was recently married at
22 years old).
I think it makes you think about things that you
wouldn't normally think about in your twenties. I
mean, I think not just dealing with the potential
mortality of a parent, which is kind of normal even if
it's at young age, you kind of, you know, think about
that. But I don't think, at twenty, most people think
about their own mortality. So, I think even in
University, when everyone's just thinking about, you
know, ‘Where am I gonna get a job?’I was thinking
about, you know, ‘What will my future be?’ (This 36-
year-old woman underwent predictive genetic testing
at age 32 after learning in her mid-twenties that her
mother, who was diagnosed with ovarian cancer, was a
mutation carrier).
If it's something that you suspect is in your family,
and it's available to get the genetic testing, I think
people should know. You're in your fifties and then
you have breast cancer, there might have been things
you could have done in your forties and your thirties.
I think it's always better to know, if you can, and then
know what you're dealing with. So, I think that's the
most important thing I try to tell people. (This 37-
year-old participant learned of the mutation in her
family in her mid-twenties and underwent genetic
testing more than 5 years later).
Discussion
Although each participant’s journey has been unique,
there are several salient themes that can be drawn from
their collective experience of being a non-carrier from a
HBOC family. The more salient of which are discussed
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cancer genetic practice and counseling.
How and when parents should disclose their mutation
status
Many factors are known to influence the communication
of genetic risk within families including the perceived rele-
vance of the information, closeness of family members,
family patterns and rules, as well as the type, amount and
timing of the information being disclosed [13]. After re-
ceiving a positive BRCA genetic test result, knowing when
and how to disclose this information to one’s offspring is a
concern for many parents.
Learning that their parent carried a deleterious BRCA
mutation as an adolescent or young adult did not seem
to have any obvious negative consequences among the
participants in our study. Bradbury and colleagues also
report that offspring learning their parent’s carrier status
before the age of 25 have a good understanding and do
not express any negative consequences pertaining to the
disclosure [6].
In contrast, we identified two participants who were not
told of their parent’s carrier status by way of direct paren-
tal communication. Rather, both discovered documents
pertaining to the presence of the mutation in their parent.
This lack of disclosure is not necessarily surprising given
the complexities and dilemmas faced by parents and the
fact that disclosure does not occur 100% of the time [14].
The experiences of these two young women were under-
standably distinct from those introduced to the notion of
a genetic mutation in the family by at least one parent. In
particular, their reaction of seeking genetic counseling and
testing soon after learning that their parent was a BRCA
carrier might have been because of the need for an explan-
ation and reassurance with regard to the crisis created by
this unanticipated discovery.
Age is an important determinant for predictive genetic
testing
According to our participants, it can be said that there is
no “perfect” time to undergo genetic testing, there exists
only a time that is “better” than others. There are many
factors that dictate when might be the most appropriate
time in a woman’s life for testing.
Since the clinical availability of BRCA testing there has
been much controversy with regard to testing adoles-
cents and young adults, as is the case with many other
adult-onset hereditary conditions. Although age is cer-
tainly a key factor, the ideal age to have genetic testing is
personal and is perceived differently by each individual.
We found that a precise age might be less important
than other factors in one’s life when considering genetic
testing. In fact, in her review, Pasacreta found that age
was not associated with one’s interest in pursuing BRCAgenetic testing and its significance in the actual
utilization of genetic testing remained unclear [11].
Among our participants, timing to be tested also
appeared to be influenced by the women’s general state
at that moment in time. To emphasize, five of the eight
women were going through a period of stress and in-
stability in their lives, according to the Holmes and Rahe
Social Readjustment Rating Scale, when they made the
decision to undergo predictive genetic testing [15].
These stress-inducing life events included the unex-
pected discovery of the familial mutation, a new cancer
diagnosis in a first degree relative, and a pregnancy. Al-
though on the surface these might appear to be inappro-
priate periods for one to have genetic testing, it can be
said that these women, because of the crisis and sense of
instability, were ripe for change and willing to incorpor-
ate the new knowledge that genetic testing would bring.
Taken all together, age is important when considering
the key psychosocial factors predicting the most appro-
priate time for a woman to undergo BRCA genetic test-
ing, however it should not be considered the sole
determinant for testing. It is also important to remember
that the decision to know one’s mutation status is much
different than the decision to act on it.
Predictors of posttest adjustment and risk perception
One of our main objectives was to describe the adjust-
ment and risk perception of mutation-negative women
after having undergone genetic testing. Although not
formally assessed with standardized items, the partici-
pants described the ways in which cancer and their mu-
tation status has affected them in ample detail.
Posttest risk was accurately expressed by the women
in our study as being similar to the population risk level,
yet most had a self-professed moderate degree of cancer
worry. This is not surprising given the results of various
studies, such as that by Quillin and colleagues [16]. The
authors found that cancer worry did not significantly
correlate with risk perception in daughters of mothers
with breast cancer. In addition, they found that cancer
worry appeared to be stable across all risk levels,
whether their actual risk of breast cancer was high or
low [16]. Similarly, a longitudinal study looking at psy-
chological distress one year following the disclosure of
BRCA predictive test results found that, while the dis-
tress levels of non-carriers decreased somewhat over
time, there was no significant difference in breast cancer
specific distress between carriers and non-carriers [17].
It is possible that we have observed a similar trend, in
that, cancer worry is elevated regardless of whether a
woman from an HBOC family is at high or low risk of
developing cancer. The underlying common variable be-
tween these groups of women is a family history of
breast cancer. This phenomenon might help to explain
Macrae et al. Hereditary Cancer in Clinical Practice 2013, 11:14 Page 8 of 11
http://www.hccpjournal.com/content/11/1/14the fact that the women in our study were able to accur-
ately state their lifetime breast cancer risk, but many did
not necessarily feel at this population risk.
Although many had a continued sense of cancer worry,
none of the women were actively seeking cancer screening
beyond what was recommended for the general population.
However, it will be interesting to know whether these
women do go on to pursue additional breast or ovarian
cancer screening in the future. In fact, it has been previ-
ously shown that the cancer screening practices of
mutation-negative woman from HBOC families far exceeds
what is recommended. It is not clear, however, if this excess
screening is patient-driven or physician-driven [18].
Furthermore, when compared to the older women
studied by Bakos and colleagues [7], adjustment and risk
perception of the young women in our study are simi-
larly influenced by their personal and familial experience
with cancer, even with a rational understanding of genet-
ics. Thus, for this younger generation of genetic savvy
women, coping as a mutation-negative member in a
HBOC family is still proving to be complicated by the
surrounding factors experienced by the generation pre-
ceding them. Therefore, what might be of interest in the
future are the experiences of subsequent generations of
women whose parents were among the predictive gen-
etic testing generation. In this case, their familial experi-
ence with cancer might be very different. For instance,
affected relatives might become more distanced from
this future generation given that mutation carriers might
remain unaffected as a result of risk-reducing procedures
or because cancer might become a less devastating dis-
ease due to improved screening options and treatments.
Just as was the case with the families studied by Kenen
and colleagues [19], the participants in our study utilized
their social and familial contexts when making sense of
their risk and how they wished to manage it.
It is important to note that we are observing these
women as a cross-sectional snapshot of their experience
and their cancer risk perception and preoccupation
might not necessarily be stable over time. At the time,
only one participant expressed ongoing cancer preoccu-
pation and worry despite the fact that her absolute risk
of developing breast and ovarian cancer was clearly
understood. Further evaluation her experience is neces-
sary to build a better sense of what the underlying fac-
tors causing this persistent preoccupation might be.
Using previously reported findings, it possible to begin
to formulate hypotheses with respect to this anomalous
patient in our study group. For one, it is known that
both general and cancer-specific distress at baseline is
highly predictive of later psychological responses in
members of BRCA mutation-positive families [11].
Hilgart and colleagues have also observed that reactions
to one’s cancer risk assessment are greatly influenced bypreconceived expectations about risk as well as one’s
personal and family history of cancer [20]. Therefore, it
is possible that the patient had elevated stress levels and
cancer worry prior to undergoing genetic testing, which
might partially explain her degree of posttest anxiety
and worry. As a result of waiting more than 10 years
after learning about the mutation in the family before
undergoing genetic testing, this participant truly em-
bodied the notion that she was mutation-positive. This
resulted in extensive preparation for being a carrier and
little time spent anticipating a negative result which,
according to the participant, had contributed somewhat
to her current state of maladjustment. Ultimately, a pa-
tient’s reaction to a genetic test result, whether positive
or negative is not constructed in isolation, but within
the context of their family history of cancer, their testing
experience, and the results of their other relatives [11].
Another approach to understanding this participant is
by way of heuristics, which are inferential cognitive
shortcuts. Heuristics are often employed in the study
cancer genetics, particularly with respect to its influence
on risk perception among members of hereditary cancer
families. To emphasize, Kenen and colleagues reported that
women utilize three main heuristics when interpreting their
breast and ovarian cancer risk, that of the representative,
availability, and illusion of control [19]. Women use these
heuristics to put complex or upsetting knowledge into per-
spective in the hopes of simplifying complicated decision
making [21]. Within the narratives of our study, all three of
these heuristics were repeatedly employed by the women,
especially when attempting to make sense of any residual
cancer worry after learning they were non-carriers.
With respect to this unique participant with excess can-
cer worry, the “simulation heuristic” might have more
relevance in explaining her current state. The simulation
heuristic was first described by Kahneman and Tversky in
1982 as a mental operation that brings things to mind by
way of mentally constructing scenarios that allows one to
answer complex questions by using this simulation model
[22]. Normally, we would consider a negative predictive
genetic test result to be a positive event and would expect
reactions such a joy and a sense of relief given the alterna-
tive outcome. However, this participant anticipated being
a carrier and even stated that part of her wished to have
been mutation-positive for various reasons. Therefore, her
view of the positive and negative outcomes of genetic test-
ing had been reversed from the norm. Consequently, her
mental simulation of being mutation-positive might have
resulted in intensified emotions and feelings of regret and
disappointment. This type of reaction is in keeping with
studies involving the theory of the simulation heuristic
[23]. In brief, in using concepts such as the simulation
heuristic, we can begin to appreciate exaggerated reactions
experienced by BRCA mutation-negative women. With
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adapt genetic counseling to anticipate and reduce this type
of adverse reaction.
How the genetic knowledge has shaped their life
Without doubt, understanding how the knowledge of the
presence of a BRCA mutation in a parent has impacted or
shaped the lives of young women is a difficult task. It is
often challenging to distinguish what has been the impact
of a potential genetic predisposition to cancer versus the fa-
milial experience of cancer itself. From the narratives of our
participants it is clear that the effects have been widespread
and significant as a result of learning about a gene mutation
that is responsible for their familial cancer experience. It
can be argued, however, that some of the effects on mar-
riage, family planning, and prophylactic surgery, for ex-
ample, were caused not only by the presence of the gene,
but also their unique experience with how the gene muta-
tion has manifested itself in their family.
In some cases, the presence of the gene mutation has
also enabled the young women to redefine their family
history of cancer. The sense of endless suffering felt by the
women can be attributed to the presence of the familial
gene mutation. However, because they are non-carriers,
there is a sense of freedom that has allowed them to focus
on others in the family, as well as their community at
large. For some, especially where prophylactic surgery was
a planned and accepted reality, the fact of being a non-
carrier has certainly altered the course of their life.
Ultimately, this “second generation” of women to
undergo predictive BRCA genetic testing are growing up
with a strong family history of cancer in addition to the
genetic knowledge and their lives and identities have been
shaped by both of these realities. As Margaret Lock and
colleagues emphasized, it is unlikely that this genetic infor-
mation will supplant one’s other identity claims. Rather, it is
more likely that this genetic identity will combine and inter-
act with other identities [24]. This is made apparent by our
group of women, whose cancer experience came first, and
for whom the genetic knowledge has only added a layer to
their overall experience of being a young women growing
up in such an environment.
To our knowledge this is the first study to report on
this particular group of women in such detail. Employing
a qualitative approach with our highly selected group of
women provided the opportunity to explore a complex
topic without the restrictions of specific hypotheses.
While a sample of 8 is deemed sufficient for in-depth
exploration [25], some might argue that a larger sample
size might have provided more variation in the emerging
themes. We later verified if any additional women would
have qualified at our institution by searching our clinical
databases for non-carriers. One hundred and ninety-six
families were identified as carrying a BRCA mutation atour institution as of 2010. In these families, 117 women
were tested and were found not to carrier their familial
BRCA mutation. Of these 117 non-carriers, any women
who was 40 years or older at the time of genetic testing
was eliminated. The age 40 was chosen as the cut-off be-
cause the youngest they would have been at the time of
disclosure would have been the mid-twenties given that
the BRCA genes were discovered in the mid-1990’s.
Forty two women remained. We then verified if the car-
rier parent was tested at least five years prior to the dis-
closure of their own test results. Only the 8 eligible
women remained who were selected as described above.
It was not possible to identify our eligible non-carriers
by this method in 2010 because our clinical database
linking non-carriers to persons with a mutation was not
created until 2012. Therefore, this audit confirmed that
our participant selection in 2010 was not bias. Using
our selection process, we were unable to capture all po-
tential non-carrier women from our carrier families be-
cause they may have been tested elsewhere, have chosen
not to be tested, or have no knowledge of their parent’s
BRCA mutation status. Previous research has shown that
patients do disclose their genetic status to first-degree
relatives but the rate of BRCA testing in at-risk relatives
is relatively low [2,26]. We could have increased the
number of potential participant by decreasing the time
interval between the parent’s and offspring’s genetic test.
However, it is unclear if this would have allowed suffi-
cient time for the family to experience their BRCA sta-
tus. In addition, by reducing the time lag, the potential
non-carriers would not have been adolescents but young
adults at the time of disclosure. Also, a time lag of at
least 5 years did not guarantee that non-carriers were
aware of their parent’s genetic status for the same inter-
val because we did not know when disclosure occurred,
as illustrated by several of our cases.
Another potential limitation is that the participants
were all English-speaking and Ashkenazi Jewish. This
population does represent a subset of women presenting
for genetic testing at our center, but given that cultural
background plays a central role in shaping one’s life, im-
portant differences might exist among other HBOC
families. Another important element of homogeneity
was that the women all had at least one first degree rela-
tive affected with breast or ovarian cancer. This proxim-
ity to disease and familial experience of cancer has likely
significantly contributed to their overall experience as a
mutation-negative woman in a mutation-positive family.
We also acknowledge that the women’s age range, as
well as the time since disclosure of the mutation in their
family, was rather broad. As outlined earlier, because of
the restrictions with regard to age and timing of genetic
testing, only a limited number of women were eligible
to be contacted.
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Testing for mutations in the BRCA genes has now been
available for more than a decade and a half. During this
time, research has uncovered many of the psychosocial
elements surrounding BRCA genetic testing, as well as
the dynamics of HBOC families. At this time we have
the beginning of a new cohort of young women who
have been aware of their parent’s mutation status since
their adolescence and have subsequently chosen to
undergo genetic testing as young adults. Prior to this
study, little was known about this group of young
women, particularly those who are found to be non-
carriers of their familial mutation. By eliciting direct pa-
tient narratives we have found that this group of women
is likely to be affected in different ways by the degree of
cancer history in the family, even with their understand-
ing of the genetic contribution to the disease.
Just as with older non-carrier women from HBOC
families, this younger generation still appears to carry a
heavy burden related to being a member of a HBOC
family. Will this still be true of subsequent generations
of HBOC families where we hope to see less cancer bur-
den through early screening and intervention? In the
meantime, the detailed narratives of these women have
provided insight that has the potential, through add-
itional research, to influence current cancer genetic
practice and counseling. Larger studies with tightened
participant characteristics, as well as studies involving
women from different cultural backgrounds, are needed
to further define the experience and needs of true nega-
tive young women from HBOC families. Of particular
interest are whether residual cancer worry in these
young women will translate into an unnecessary increase
in cancer screening in the future and whether a better
social prototype for non-carrier women will be available
so that they may have the support needed to help under-
stand their risks as well as their place within their
family.
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